Overview

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, phase 1/1b study of the pressure-enabled intrapancreatic infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with locally advanced pancreatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
TriSalus Life Sciences, Inc.